Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study of Chimeric HER-2 Antigen Receptor-modified T Cells in Chemotherapy Refractory HER-2 Advanced Solid Tumors

NCT01935843 is registered in ClinicalTrials.gov with Chinese PLA General Hospital as lead sponsor.

NCT NCT01935843
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01935843 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study of Chimeric HER-2 Antigen Receptor-modified T Cells in Chemotherapy Refractory HER-2 Advanced Solid Tumors
Lead sponsor
Chinese PLA General Hospital
Phase
Phase 1/2
Overall status
Unknown status
Start date
September 30, 2013
Completion date
September 30, 2017
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced her-2 positive solid tumors, chemotherapy refactory, her-2 antibody inhibitor therapy refactory